Literature DB >> 18722023

Autoimmune channelopathies: John Newsom-Davis's work and legacy. A summary of the Newsom-Davis Memorial Lecture 2008.

Angela Vincent1.   

Abstract

John Newsom-Davis was a key figure in the field of neuroimmunology and combined many outstanding personal qualities with considerable clinical and scientific expertise. His first report of plasma exchange in myasthenia in the late 1970s demonstrated its use both as a treatment and as an experimental tool to establish the pathogenic role of antibodies in neurological disorders. Subsequent investigations into the Lambert Eaton myasthenic syndrome and acquired neuromyotonia showed that these were caused by antibodies to specific ion channels. The field of autoimmune channelopathies is continuing to expand with identification of new antibody-mediated diseases including those affecting the central nervous system. This review will highlight some of his most seminal findings and those that are following on from his work.

Entities:  

Mesh:

Year:  2008        PMID: 18722023     DOI: 10.1016/j.jneuroim.2008.07.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.

Authors:  Sarosh R Irani; Sian Alexander; Patrick Waters; Kleopas A Kleopa; Philippa Pettingill; Luigi Zuliani; Elior Peles; Camilla Buckley; Bethan Lang; Angela Vincent
Journal:  Brain       Date:  2010-07-27       Impact factor: 13.501

2.  Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodies.

Authors:  Edward Littleton; Mathias Dreger; Jackie Palace; Angela Vincent
Journal:  Mol Cell Proteomics       Date:  2009-03-29       Impact factor: 5.911

Review 3.  Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?

Authors:  Shenghua Zong; Carolin Hoffmann; Marina Mané-Damas; Peter Molenaar; Mario Losen; Pilar Martinez-Martinez
Journal:  Front Immunol       Date:  2017-07-05       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.